Article from April 2014 edition of the Journal of Thoracic Oncology
Ultra-deep sequencing of circulating free dna to identify predictive, mutated hsp90 clients in galaxy-1 (nct01348126), a randomized phase 2b study of ganetespib plus docetaxel versus docetaxel alone in 2nd line advanced nsclc
A team of UK and USA researchers, led by Prof. Dean Fennell of the Thoracic Medical Oncology Department, University Hospital of Leicester, UK, performed a prospective exploratory liquid biopsy analysis with the aim of identifying somatic mutations in plasma as predictors of clinical outcome with ganetespib in the GALAXY-1 trial. They showed that ultra-deep sequencing of multiple somatic mutations in circulating free DNA is feasible and provides a new potential for understanding the evolution of tumour heterogeneity and mechanisms of resistance. The results were presented in a poster discussion session at 4th European Lung Cancer Conference (26-29 March 2014, Geneva, Switzerland).
The establishment of a predictive biomarker is always useful for treating patient populations that have differing results from therapeutic use of a particular drug. If this biomarker turns out to be highly predictive of patients that would benefit from ganetespib use it could potentially identify individuals that would benefit from sole therapy with ganetespib. At the very least it will identify patients that would benefit from adding ganetespib to ongoing therapy.
With all of that said....the potential for FDA approval with a successful biomarker in place improves tremendously.